Immunohistochemical expression of angiogenic cytokines in childhood Hodgkin lymphoma

Pathology, Research and Practice
E Caglar CitakNalan Akyurek

Abstract

This immunohistochemical study was carried out to evaluate the role of vascular endothelial growth factor (VEGF), matrix metalloproteinase-2 and -9 (MMP-2 and MMP-9), their inhibitor (tissue inhibitor of metalloproteinase-1, TIMP-1), and microvessel density (MVD) in the clinicopathologic behavior of childhood Hodgkin's lymphoma (HL). Paraffin-embedded histologic sections from 15 children with HL were immunohistochemically stained with MMP-2, MMP-9, TIMP-1, VEGF, and CD31 antibodies to investigate the correlation between the expression of these markers and the clinicopathologic characteristics of HL. Expression of MMP-2 and VEGF in Hodgkin and Reed-Sternberg cells (HRS) was more frequent in nodular sclerosis than in other subtypes (p=0.07 and 0.08, respectively). None of the study parameters in HRS cell were associated with age, sex, disease stage, extranodal disease, and the occurrence of bulky tumor. There was a trend toward advanced stage in negative TIMP-1 staining in HRS cells (p=0.06). In reactive lymphocytes, MMP-2 expression was correlated with MVD (r=0.68, p=0.005), and MMP-9 expression was correlated with B symptoms (p=0.003). Also, low TIMP-1 expression in reactive lymphocytes was frequently found in patients with adv...Continue Reading

References

Dec 9, 1997·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A VaccaF Dammacco
Jun 26, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·L M EllisD B Evans
Mar 10, 2000·Biochimica Et Biophysica Acta·K BrewH Nagase
Jul 8, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Y ShimadaM Imamura
Sep 5, 2002·The Journal of Pathology·Ipatia A Doussis-AnagnostopoulouKevin C Gatter
Mar 29, 2003·Journal of Hematotherapy & Stem Cell Research·Domenico RibattiDenis English
Jun 17, 2003·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Woo Sung MoonAndrzej S Tarnawski
Jan 28, 2004·Birth Defects Research. Part C, Embryo Today : Reviews·Lorraine E Harry, Ewa M Paleolog
Feb 14, 2004·European Journal of Haematology·Heli PennanenTaina Turpeenniemi-Hujanen
Jul 30, 2004·Journal of Surgical Oncology·Axel KleespiesChristiane J Bruns
May 4, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Henni RuokolainenTaina Turpeenniemi-Hujanen
Jun 21, 2005·Journal of Cellular and Molecular Medicine·Joyce E Rundhaug
Aug 9, 2005·The Journal of Surgical Research·Kristin BjørnlandGunhild M Maelandsmo
Jul 1, 2006·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Mads Nikolaj Holten-AndersenIb Jarle Christensen
Jun 27, 2013·World Journal of Gastroenterology : WJG·Alireza RafieiD Scott Merrell

❮ Previous
Next ❯

Citations

Jun 25, 2014·Leukemia Research·Christian MarinaccioDomenico Ribatti
Jul 10, 2010·Pediatric Hematology and Oncology·Agnieszka Mizia-MalarzHalina Wos
Oct 28, 2008·Pathology, Research and Practice·Freda H PassamNikolaos M Siafakas

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.